A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology
- Resource Type
- Article
- Source
- In
ESMO Open October 2023 8(5) - Subject
Phase I Trials - Language
- ISSN
- 2059-7029